Jiangsu Hengrui chairman steps down; plus Ovid, Verrica and Elevar
The chairman of Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Zhou Yunshu, is resigning for health reasons. Former Chairman Sun Piaoyang, who is now a director, will be interim chairman.
As Ovid Therapeutics Inc. (NASDAQ:OVID) shifts its focus towards its early-stage pipeline, former Chief Commercial Officer Jason Tardio has been named COO, and Claude Nicaise, who served as Ovid’s EVP, regulatory, was appointed as head of R&D. Additionally, Amit Rakhit will step down as president and CMO in August and join the neuroscience company’s scientific and clinical advisory board, while Michael Poole joined the board of directors. Poole previously served as head of the neuroscience innovative medicines unit at AstraZeneca plc (LSE:AZN; NYSE:AZN). ...